Diseases & Conditions
New drug shows promise for early Alzheimer's disease
Researchers from the biotechnology company Biogen have reported that a new drug reduced the amount of amyloid plaques—the brain deposits associated with dementia—and slowed cognitive decline in people with early Alzheimer's disease. They presented the report March 20, 2015, at the International Conference on Alzheimer's and Parkinson's Diseases in Nice, France.
The researchers studied 166 people ages 50 to 90 who had been diagnosed with mild Alzheimer's. The participants were randomly assigned to receive either a placebo or one of four different doses of the drug aducanumab—an antibody that attaches to amyloid deposits and turns the immune system on them.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
